H.C. Wainwright starts vTv Therapeutics with 'buy' as diabetes drug study set to resume
ReutersApr 9, 2025 11:59 AM
Drug developer vTv Therapeutics' shares VTVT.O rise 3.2% to $16.3 premarket
Brokerage H.C. Wainwright starts coverage with "buy" rating, sets PT at $36
The new price target is more than double the stock's last close
Brokerage says a late-stage study of "underappreciated" diabetes therapy is set to resume in Q2 after the FDA lifted the clinical hold in March 2025
Company is testing cadisegliatin, an oral adjunctive therapy to insulin for treatment of type 1 diabetes
Brokerage believes overhang has been lifted from VTVT's shares and company can now enroll the patients in the late-stage study
Up to last close, stock up 14.4% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
National Debt Bomb Ignited? Musk Warns U.S. Will Be 1000% Bankrupt Without AI
TradingKey - Tesla (TSLA) CEO Elon Musk recently issued another warning regarding the rapidly ballooning U.S. national debt. He stated clearly that without artificial intelligence and robotics, the United States will inevitably head toward fiscal bankruptcy.TradingKey
10 hours ago
Tesla Stock Outlook: Competing With Rivian, Robotaxi Potential, and 2026 Prospects
There is much conversation about the prospect of investing in Tesla (TSLA) as we move closer to 2026. The volatility of its share price in 2025 is leading many investors to consider if they should purchase shares of Tesla given the alternatives available in terms of electric vehicles (Rivian, etc.).TradingKey
10 hours ago
A Crash After a Surge: Why Silver Lost 40% in a Week?
TradingKey - Spot silver (XAGUSD) prices continue to decline. Silver plunged 20% on Thursday, breaking below $71 per ounce, with the sell-off intensifying on Friday as prices fell further below $64. Compared to the all-time high set on January 29, silver prices have retraced more than 40%, wiping out nearly all gains accumulated over the previous month.TradingKey
Fri, Feb 6
Is Bitcoin’s Four-Year Cycle Dead in 2026?
Is the Bitcoin 4-year cycle dead? After 2025 broke historical records with a red post-halving year, institutional analysts explore if the Bitcoin price has decoupled from the halving countdown. Analyze the impact of spot ETFs, global liquidity, and the roadmap to the 2028 halving in this 2026 marketTradingKey
Wed, Feb 4
